Ufuk Camanli

Ufuk Camanli

Auto-generated profile, based on publicly available information

Ufuk Camanli

Department of Medical Oncology University of Health Sciences Izmir City Hospital Izmir Turkey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2025 in Nature and Science of Sleep
Verified
Journal Article
Open access
PDF file
HTHalil Taskaynatan
Halil Taskaynatan
BEBetul Ersoz
Betul Ersoz
UCUfuk Camanli
Ufuk Camanli
BGBaris Gezici
Baris Gezici
FTFeyza Arslan Tan
Feyza Arslan Tan
OUOlcun Unal
Olcun Unal
Purpose: Insomnia places significant physical and psychological burdens on female cancer patients undergoing chemotherapy, affecting their quality of life. This study aimed to investigate the prevalence of insomnia and its associated factors in female outpatients receiving chemotherapy. Patients and Methods: A cross-sectional study was conducted with female cancer patients receiving chemotherapy. The questionnaire included items assessing sociodemographic and clinical characteristics. Insomnia was measured using the Insomnia Severity Index. Results: A total of 206 female patients undergoing chemotherapy were included, with a mean age of 56.1 years (SD ± 11.7). The most common cancer types were breast (57.3%), gastrointestinal (22.8%), and gynecological malignancies (19.9%). Based on the Insomnia Severity Index (ISI), 34.0% of participants had subclinical insomnia and 17.0% had clinical insomnia. Increasing age was significantly associated with lower insomnia severity (aOR: 0.971; 95% CI: 0.945– 0.998; p = 0.038). Among gynecological cancer patients, insomnia was more prevalent in those receiving treatment for metastatic disease (76.2% vs 35.0%). Psychiatric conditions (depression and/or anxiety) requiring medication and the presence of pain were both significantly associated with higher rates of insomnia (p < 0.001 for both). Conclusion: Insomnia was highly prevalent among female cancer patients undergoing chemotherapy. Younger age, presence of pain, psychiatric comorbidities (particularly depression and/or anxiety), and metastatic disease status emerged as significant correlates. Considering the relationship between insomnia and physical and psychological distress, it is anticipated that regular screening and treatment approaches for insomnia will contribute to the holistic cancer care process by improving patient quality of life.

7 April 2025 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
NANargiz Majidova Altuntash
Nargiz Majidova Altuntash
SYSendag Yaslikaya
Sendag Yaslikaya
MMMartin Mildanoğlu
Martin Mildanoğlu
ACAlper Coskun
Alper Coskun
DUDuygu Ercan Uzundal
Duygu Ercan Uzundal
OKOsman Köstek
Osman Köstek
Background/Aims: The treatment of hepatocellular carcinoma (HCC), which accounts for 90% of all liver cancers, is highly varied. The use of second-line treatments following progression on first-line atezolizumab and bevacizumab (Atez/Bev) for advanced HCC remains controversial. The aim of this study was to analyze the real-world clinical results of second-line treatments in progression after Atez/Bev and to determine the factors affecting prognosis. Materials and Methods: Fifty-eight patients treated with second-line sorafenib, regorafenib, and cabozantinib for progression after first-line Atez/Bev for advanced/metastatic HCC from 20 centers in Türkiye between October 2020 and June 2024 were retrospectively analyzed. Responses were evaluated by Response criteria, specifically Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria. Median overall survival (OS) and progression-free survival (PFS) were computed with the Kaplan–Meier method. The Cox regression model was utilized to analyze multivariate analyses. Results: About 82.8% of the patients were male and the median age of the whole group was 62 (range, 18-78) years. All patients progressed after first-line Atez/Bev and were given second-line treatment. The most commonly used second-line treatment option was sorafenib (70.7%), followed by regorafenib (12.1%) and cabozantinib (10.3%). Both median PFS (4.1 months) and median OS (7.8 months) were longer in patients treated with sorafenib compared to other treatments. In univariate analyses, Child–Pugh score B, alpha-fetoprotein (AFP) levels (>200 ng/mL), extrahepatic spread, and Prognostic Nutritional Index (PNI) < 47.6 substantially raised the risk of overall mortality. Multivariate analysis showed that extrahepatic spread (HR (Hazard ratio): 0.41, P = .012), PNI level (HR: 0.24, P =.005), and AFP level (HR:1.97, P = .049) were independent predictors of OS. Conclusion: Although second-line therapies after Atez/Bev show different degrees of efficacy, survival rates are consistent with the literature. Extrahepatic spread, AFP level, and PNI level are the main prognostic factors. In light of this information, personalized treatment strategies may improve outcomes for this challenging patient group. Cite this article as: Majidova N, Yaslıkaya S, Mıldanoglu MM, et al. Efficacy of second-line treatments after atezolizumab and bevacizumab in advanced hepatocellular carcinoma and related prognostic factors: A multicenter study by the turkish oncology group (TOG). Turk J Gastroenterol. 2025;36(5):293-301.